Case Report: Adrenal Pathology Findings in Severe COVID-19: An Autopsy Study

Monique Freire Santana,1,2,3 Mayla Gabriela Silva Borba,2,4 Djane Clarys Baia-da-Silva,1,2 Fernando Val,1,2 Márcia Almeida Araújo Alexandre,1 José Diego Brito-Sousa,1,2 Gisely Cardoso Melo,1,2 Marcos Vinicius Oliveira Queiroga,4 Maria Eduarda Leão Farias,3 Cecilia Cunha Camilo,6 Felipe Gomes Naveca,5 Mariana Simão Xavier,6 Wuelton Marcelo Monteiro,1,2 Guilherme Augusto Pivoto João,1 Ludhmila Abrahão Hajjar,7 Jaume Ordi,8 Marcus Vinicius Guimarães Lacerda,1,5* and Luiz Carlos Lima Ferreira1,2

1 Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil; 2 Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil; 3 Departamento de Ensino e Pesquisa, Fundação Centro de Controle de Oncologia do Estado do Amazonas – FCECON, Manaus, Brazil; 4 Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Brazil; 5 Fundação Oswaldo Cruz, Instituto de Pesquisas Leónidas and Maria Deane, Manaus, Brazil; 6 CDL – Laboratórios Santos e Vidal, Manaus, Brazil; 7 Universidade de São Paulo – USP, São Paulo, Brazil; 8 Hospital Clinic de Barcelona, Barcelona, Spain

Abstract. Although high mortality has been reported in many COVID-19 studies, very limited postmortem information from complete autopsies is available. We report the findings in the adrenal glands in 28 autopsies with confirmed SARS-CoV-2 infection. Microscopic lesions were identified in the adrenal glands in 12/28 patients (46%). Seven cases showed necrosis, generally ischemic; four showed cortical lipid degeneration; two showed hemorrhage; and one unspecific focal adrenalitis. Vascular thrombosis in one patient and focal inflammation in association with other findings in three patients were observed. No case presented adrenal insufficiency. In conclusion, adrenal lesions are frequent in patients with severe COVID-19. The lesions are mild but could contribute to the lethal outcome.

The current COVID-19 pandemic caused by SARS-CoV-2 has lasted for about 6 months in more than 10 million cases worldwide after the first cases were detected in China in late 2019. In mild cases, the infection is usually self-limited and does not require specialized care. Patients with severe COVID-19, however, often require intensive care because of respiratory failure.1 Exacerbated inflammation due to a cytokine storm leads to rapid multiple organ failure and fatal damage to the lungs, kidneys, and heart,2 and has been shown as a key pathogenetic mechanism in these severe COVID-19 cases.

This intense inflammatory process is commonly associated with the activation of coagulation.3 This phenomenon is also observed in infections by Neisseria meningitidis, Mycobacterium tuberculosis, Cytomegalovirus, Ebola, and Histoplasma capsulatum, and frequently evolves to adrenal injury due to hemorrhage and/or thrombosis.4 However, adrenal complications have not been reported in COVID-19 patients so far.

Complete autopsies were performed on 28 deceased patients with SARS-CoV-2 infection confirmed by reverse transcription quantitative polymerase chain reaction5 of nasopharyngeal/oropharyngeal swab samples from the referral hospital for severe COVID-19 infections in Manaus (Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz) in the Western Brazilian Amazon. Signed informed consent was obtained from the legal representatives in all cases. All patients were examined between March and May 2020. Autopsies were conducted in the same hospital by a single pathologist, with the help of trained technicians, under strict biosafety rules. Specimens were fixed in neutral buffered formalin, paraffin embedded, and routinely stained with hematoxylin and eosin. All cases were examined by two different pathologists, blind to each other. In case of discrepancy, an adjudication meeting was held, and a consensus was reached. Clinical, macroscopic, and microscopic data were systematically registered in Research Electronic Data Capture standard forms.

The autopsy study showed adrenal lesions in 12 of the 28 patients (42.9%) who died with severe COVID-19 (Table 1; see Figure 1 for most representative macroscopic and microscopic images of adrenal involvement in COVID-19 in five patients). Seven cases showed necrosis, which was generally ischemic necrosis (four cases). Four cases showed cortical lipid degeneration, two showed hemorrhage, and one unspecific focal adrenalitis. Focal inflammation was observed in association with other findings in three patients, whereas vascular thrombosis was seen in one patient. Overall, focal inflammation was identified in 4/28 patients (14%). In one of the patients, adrenal cortical carcinoma was detected as an incidental finding. Most of these patients were male (10/12 or 83.3%), aged 34–88 years, and 10 (83.3%) presented known comorbidities including alcoholism, smoking, and obesity (Table 1).

After the autopsy findings, stored samples of plasma collected 1 or 2 days before death were sent for cortisol measurement, by quimioluminescence. No cortisol was less than 10 μg/dL (Table 1), which is a reliable and widely available laboratorial marker of adrenal insufficiency in critical patients in practice.6 All patients had been treated with wide-spectrum antibiotics and vasopressors (mostly norepinephrine) at some stage of the hospitalization, and only patients 11 and 12 used corticoid therapy (hydrocortisone).

Because of biosafety concerns, very few pathology laboratories worldwide have been able to perform full autopsies of COVID-19 patients. Therefore, most of the series are based on minimally invasive autopsies (MIAs),7–9 in which adrenal glands are not generally accessible. However, MIAs can be useful for COVID-19 death surveillance purposes and the study of more accessible target organs, such as lungs. Only one series has examined the adrenal glands in five cases; this study reported only minor vascular damage in the adrenal glands.10 In this series, the fibrinoid hyaline vasculopathy in peri-adrenal vessels found was directly related to atherosclerosis in patients with systemic arterial hypertension and diabetes mellitus, and, consequently, considered as more related to the preexisting
One major limitation of our series was the lack of pulmonary microthrombi reported as a common feature in COVID-19 patients. In our study, adrenal lesions were frequently observed in patients who died with severe COVID-19 (46%). The detected lesions (necrosis, cortical lipid degeneration, hemorrhage, and focal inflammation) were possibly directly linked to the viral infection, as no associated lesions were identified. However, microthrombi were identified in one patient as opposed to pulmonary microthrombi reported as a common finding in COVID-19. One major limitation of our series was the lack of viral identification in the adrenal glands, making it possible that the findings could also be explained by another nonspecific systemic end-stage fatal disease. In all cases, however, the major cause of death on postmortem examination was attributed to SARS-CoV-2 infection, and extensive lung commitment was the major complication directly related to death.

In four of our COVID-19 cases, the adrenal cells presented cortical lipid degeneration, characterized by the accumulation of clear vacuoles within cortical cells. Cortical lipid degeneration (vacuolization) has been shown to occur as a response to stress, such as drugs and toxins, or infection.

In stressful situations, adrenal receptors are activated and induce the synthesis of steroidogenic enzymes as well as cholesterol production and transportation (which can potentially accumulate), culminating in the production and release of glucocorticoids.

Corticosteroids have a potential role in controlling the host inflammatory response, potently inhibiting cytokine production and restoring inappropriately low endogenous levels of cortisol. Adrenal damage compromises the regulation of inflammation and may be harmful. Some infectious agents affect the adrenal gland, leading to refractory shock, the classical Waterhouse–Friderichsen syndrome.

In critically ill patients, catecholamines released in the procoagulant environment may cause vasocostriction in adrenal veins, resulting in venous thrombosis and adrenal necrosis. The use of exogenous vasopressors may enhance this process. Of 78 patients with adrenal necrosis, 41% had thrombosis of the main adrenal vein and the capsular veins. Venous thrombosis can occur in most of the cases in patients with severe infection, especially in the respiratory tract, and bacterial infections. Unilateral adrenal hemorrhage and necrosis, features identified in most of the reported patients, may result from direct damage to the adrenal or blood supply.

The moderate adrenal injuries observed in this series suggest a need for further full autopsy studies to clarify their role in the mechanism leading to death in these patients. Therefore, corticosteroid efficacy against COVID-19, as recently shown (Recovery trial), is probably fundamented on its pulmonary anti-inflammatory properties.

Received July 1, 2020. Accepted for publication August 25, 2020.

Published online August 31, 2020.

Acknowledgments: We would like to thank the families who, in times of grief, allowed the autopsies to be conducted to provide further insight into COVID-19. Also, we thank all personnel from Hospital e Pronto Socorro Delphina Rinaldi Abel Aziz, Departamento de Patologia e Medicina Legal (Universidade Federal do Amazonas) and R. B. Patologia for their assistance with data collection. Publication charges for this article were waived due to the ongoing pandemic of COVID-19.

Financial support: This study was funded by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Departamento de Ciência e Tecnologia/Ministério da Saúde (DECI), Ministério da Ciência, Tecnologia e Inovações (MCT), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, grant 403253/2020-9), Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM) (PAPAC 005/2019 and Pró-Estado public calls).

Disclosure: W. M. M., F. G. N., and M. V. G. L. are CNPq fellows. The funders had no role in study design, data collection, manuscript preparation, or decision to publish.

Authors’ addresses: Monique Freire Santana, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil, and Departamento de Ensino e Pesquisa, Fundação Centro de Controle de Oncologia do Estado do Amazonas – FCECON, Manaus, Brazil, E-mail: monique.freire20@gmail.com, Mayla Gabriela Silva Borba, Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil, and Hospital e Pronto Socorro Delphina Rinaldi Abel Aziz, Manaus, Brazil, E-mail: maylagsborba@gmail.com, Djane Clarys Baia-da-Silva, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado,

---

### Table 1

Demographics and plasma cortisol of patients with adrenal gland microscopic findings

| Patient | Age/gender | Comorbidities | Days of disease before death | Cortisol 24–48 hours before death (μg/dL) | Adrenal glands |
|---------|------------|---------------|-----------------------------|------------------------------------------|---------------|
| 1       | 57/M       | –             | 10                          | NA                                       | Ischemic necrosis |
| 2       | 34/M       | Alcoholism and smoking | 17                          | 54.2                                     | Hemorrhagic necrosis |
| 3       | 66/M       | Hypertension and smoking | 11                          | 43.5                                      | Focal ischemic necrosis |
| 4       | 65/M       | Alcoholism and Parkinson | 55                          | 65.8                                      | Cortical lipid degeneration and focal adrenalitis |
| 5       | 88/M       | Coronary insufficiency | 12                          | 23.5                                     | Ischemic necrosis |
| 6       | 65/F       | –             | 10                          | 67.2                                     | Cortical lipid degeneration and focal adrenalitis |
| 7       | 48/M       | Obesity       | 22                          | 14.6                                     | Ischemic necrosis |
| 8       | 55/M       | Smoking       | 19                          | 73.2                                     | Hemorrhagic necrosis |
| 9       | 50/F       | Obesity and chronic kidney diseases | 12                          | 41.5                                     | Cortical lipid degeneration |
| 10      | 35/M       | Obesity and alcoholism | 21                          | 41.9                                     | Cortical lipid degeneration and focal adrenalitis |
| 11      | 52/M       | Diabetes mellitus, alcoholism, smoking, and gout | 12                          | 80.7                                     | Focal necrosis and focal adrenalitis |
| 12      | 70/M       | Alcoholism and smoking | 23                          | 70.1                                     | Focal adrenalitis |

F = female; M = male; NA = not available. Obesity: body mass index > 30; cortisol reference levels: 4.3–22.4 μg/dL. Focal adrenalitis: unspecific presence of lymphocytes; Ischemic necrosis: more than ~40% of the gland was compromised.
FIGURE 1. Adrenal pathology autopsy findings in five severe COVID-19 patients. Enlarged right adrenal gland with extensive areas of hemorrhagic necrosis (A) (patient 8), bar = 2 cm. Histologic section of the adrenal with extensive adrenal hemorrhage (B) (patient 8), thrombi fibrin (C) (patient 8), hemorrhagic necrosis (D) (patient 2), focal adrenalitis (E) (patient 12), and adrenocortical carcinoma (F) (patient 4). Adrenal cortex with diffuse and severe cortical vacuolization of macro- and microvacuolar lipidic deposits (G) (patient 8). Hematoxylin–eosin–stained tissues observed under ×400 original magnification.
Manaus, Brazil, and Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil, E-mail: djane.claryss@gmail.com. Fernando Val, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, and Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil, E-mail: ffaval@gmail.com. Márcia Almeida Araújo Alexandre, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, E-mail: marcialeandre@gmail.com. Diego Jose Brito-Sousa, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, Brazil, E-mail: marceloemail@gmail.com. Gisely Cardoso, Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil, and Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil, E-mail: sousajdb@live.com. Maria Eduarda Leão Farias, Fundação Oswaldo Cruz, Rinaldi Abdel Aziz, Manaus, Brazil, E-mail: marcosqueirogares@gmail.com. Fernando Val, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, and Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil, E-mail: marcosqueirogares@gmail.com. Luiz Carlos Lima Ferreira, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, E-mail: ferreira.luiz@gmail.com. Wuelton Marcelo Monteiro, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, and Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil, E-mail: wueltonmm@gmail.com. Guilherme Augusto Pivoto João, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, and Fundação Oswaldo Cruz, Instituto de Pesquisas Leônidas & Maria Deane, Manaus, Brazil, E-mail: meduardaeano@gmail.com. Cecília Cunha Camilo, CDL – Laboratórios Santos e Vidal, Manaus, Brazil, E-mail: cecilia.camilo@yahoocom.br. Felipe Gomes Naveca, Fundação Oswaldo Cruz, Instituto de Pesquisas Leônidas & Maria Deane, Manaus, Brazil, E-mail: naveca.felipe@gmail.com. Mariana Simão Xavier, Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil, E-mail: marianasimaoxavier@gmail.com. Wuelton Marcelo Monteiro, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, and Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil, E-mail: wueltonnm@gmail.com. Guilherme Augusto Pivoto João, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, and Fundação Oswaldo Cruz, Instituto de Pesquisas Leônidas & Maria Deane, Manaus, Brazil, E-mail: guilherme.pivoto@hotmail.com. Luízmlhlia Abrahamo Hajjar, Universidade de São Paulo – USP, São Paulo, Brazil, E-mail: luchmlhlia@gmail.com. Jaume Ordí, Hospital Clínic de Barcelona, Spain, E-mail: jaume.ordi@global.org. Marcus Vinícius Guimarães Lacerda, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, and Fundação Oswaldo Cruz, Instituto de Pesquisas Leônidas & Maria Deane, Manaus, Brazil, E-mail: marcoslacerda.br@gmail.com. Luiz Carlos Lima Ferreira, Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, and Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil, E-mail: ferreira.luiz@gmail.com.

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Guan W et al., 2020. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 382: 1708–1720.
2. Shimabukuro-Vornhagen A, Gödel P, Soldan K, Schlöfer HA, Schlüer M, Kochanek M, Böll B, von Bergwelt-Baildon MS, 2018. Cytokine release syndrome. J Immunother Cancer 6: 56.
3. Whyte CS, Morrow GB, Mitchell JL, Chowdry P, Mitch NJ, 2020. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombotic drugs to treat COVID-19. J Thromb Haemost 18: 1548–1555.
4. Bornstein SR, 2009. Predisposing factors for adrenal insufficiency. N Engl J Med 360: 2328–2339.
5. Centers for Disease Control and Prevention, 2020. CDC 2019–Novel Coronavirus (2019–nCoV) Real-Time RT-PCR Diagnostic Panel. Available at: https://www.cdc.gov/media/134922/download. Accessed May 13, 2020.
6. Annane D et al., 2017. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I). Crit Care Med 45: 2078–2088.
7. Almeida Monteiro RA, de Oliveira EP, Nascimento Saldiva PH, Dolnikoff M, Duarte-Neto AN, 2020. Histological-ultrasonographical correlation of pulmonary involvement in severe COVID-19. Intensive Care Med 3: 1–3. Available at: https://link.springer.com/article/10.1007/s00134-020-06125-z. Accessed June 27, 2020.
8. Dolnikoff M, Duarte-Neto AN, Almeida Monteiro RA, Silva LFF, Oliveira EP, Nascimento Saldiva PH, Mauad T, Negri EM, 2020. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost 18: 1517–1519.
9. Yao XH et al., 2020. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi 49: 411–417.
10. Iuga AC, Marboe CC, Yilmaz MM, Leftkowitch JH, Gauran C, Lagana SM, 2020. Adrenal vascular changes in COVID-19 autopsies. Arch Pathol Lab Med. Available at: http://www.ncbi.nlm.nih.gov/pubmed/32579380. Accessed June 27, 2020.
11. Ackermann M et al., 2020. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 383: 120–128.
12. National Toxicology Program, U.S. Department of Health and Human Services, 2020. Adrenal Gland, Cortex – Vascularization, Cytoplasmic. Available at: https://ntp.niehs.nih.gov/nnl/endocrine/ adrenal/cxvacuol/index.htm. Accessed May 13, 2020.
13. Xing Y, Edwards MA, Ahlem C, Kennedy M, Cohen A, Gomez-Sanchez CE, Rainey WE, 2011. The effects of ACTH on steroid metabolomic profiles in human adrenal cells. J Endocrinol 209: 327–335.
14. Hui DS, Lee N, Chan PK, 2013. Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res 98: 410–416.
15. Khwaja J, 2017. Bilateral adrenal hemorrhage in the background of Escherichia coli sepsis: a case report. J Med Case Rep 11: 72.
16. Nambiar VK, Chalappurath DR, 2019. Thrombotic Tendencies in Excess Catecholamine States, Biogenic Amines in Neurotransmission and Human Disease. Ahmed Uçar: IntechOpen. Available at: https://www.intechopen.com/books/biogenic-amines-in-neurotransmission-and-human-disease/thrombotic-tendencies-in-excess-catecholamine-states. Accessed May 13, 2020.
17. Fox B, 1976. Venous infarction of the adrenal glands. J Pathol 119: 65–89.
18. Adorno IF, Tibana TK, de Lima GCS, de Assis Martins L, Gutierrez Junior W, Goldman SM, Nunes TF, 2019. Acute spontaneous unilateral adrenal hemorrhage: etiology and imaging findings in six cases. Radiol Bras 52: 12–16.
19. Guaran J, Paddock CD, Bartlett J, Zaki SR, 2008. Adrenal gland hemorrhage in patients with fatal bacterial infections. Mod Pathol 21: 1113–1120.
20. The RECOVERY Collaborative Group, 2020. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med NEJMoa2021436. Available at: https://doi.org/10.1056/NEJMoa2021436. Accessed July 13, 2020.